Biotech News

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex (VCNX)Vaccinex2025-03-07 22:15 ESTCompany update

ROCHESTER, N.Y. , March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of

Related news

FATEFate Therapeutics2026-09-16 11:00 EST

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

FATEFate Therapeutics2026-10-02 11:00 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

CHRSCoherus BioSciences, Inc.2026-09-23 13:30 EST

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

RVMDRevolution Medicines2026-07-29 20:05 EST

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

View all latest news

Vaccinex

Vaccinex is a biotechnology company focused on antibody therapies and immunology, with a history of pursuing difficult oncology and neurodegenerative targets. Its story is tied to platform science and the challenge of turning it into durable value.

Recent company news

VCNXVaccinex2026-04-30 00:05 EST

Vaccinex Reports 2025 Annual Financial Results

VCNXVaccinex2025-12-23 13:01 EST

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

VCNXVaccinex2025-05-27 12:45 EST

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

VCNXVaccinex2025-04-21 12:45 EST

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

VCNXVaccinex2025-03-07 22:15 EST

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Stock data

Close: 1.03 USD
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States